Fluticasone Propionate
FDA-approved product (ointment, topical), marketed as Armonair Digihaler, Armonair Respiclick, Cutivate and 9 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Allergic rhinitis
- Asthma
- Atopic eczema
- Chronic bronchitis
- Chronic obstructive pulmonary disease
- Emphysema
- Nasal Cavity Polyp
- Nasal congestion
- Nasal polyposis
- Seasonal allergic rhinitis
- Skin disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids, potent (group iii); Corticosteroids; Glucocorticoids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Fluticasone Propionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
NCT00736801 · start 2005-09
Registered record
- Registry ID
- NCT00736801
- Conditions
- Allergic Asthma
- Interventions
- Salmeterol and Salmeterol / Fluticasone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2007-04
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAllergic AsthmaInterventionSalmeterol and Salmeterol / FluticasonePhaseNot applicableRegistry statusCompletedThe Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry
NCT00402207 · start 2005-08
Registered record
- Registry ID
- NCT00402207
- Conditions
- Asthma
- Interventions
- extrafine HFA-beclomethasone; HFA-fluticasone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-08
- Completion
- 2006-10
- Enrolment
- 33
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionextrafine HFA-beclomethasone; HFA-fluticasonePhaseNot applicableRegistry statusCompletedProtopic Ointment in Adult Atopic Eczema of the Face
NCT00690105 · start 2004-02
Registered record
- Registry ID
- NCT00690105
- Conditions
- Dermatitis, Atopic
- Interventions
- tacrolimus 0.1%; fluticasone 0.005 %
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-02
- Completion
- 2005-07
- Enrolment
- 577
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDermatitis, AtopicInterventiontacrolimus 0.1%; fluticasone 0.005 %PhasePhase 4Registry statusCompletedComparison of Two Treatment Regimens in Asthmatic Patients
NCT01488773 · start 1995-04
Registered record
- Registry ID
- NCT01488773
- Conditions
- Asthma
- Interventions
- first prescription of montelukast; first prescription of salmeterol
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 1995-04
- Completion
- 2006-06
- Enrolment
- 132
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionfirst prescription of montelukast; first prescription of salmeterolPhaseNot recordedRegistry statusCompletedExpanded Access Protocol for Patients With Eosinophilic Esophagitis
NCT05095116
Registered record
- Registry ID
- NCT05095116
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011 3 mg HS
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- No longer available
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEosinophilic EsophagitisInterventionAPT-1011 3 mg HSPhaseNot recordedRegistry statusNo longer available